Purpose: Hot flash (HF) is a common side effect in prostate cancer patient undergoing androgendeprivation therapy (ADT). In this study, we evaluated the efficacy of paroxetine (selective serotonin reuptake inhibitors (SSRIs)) for HF. Patients and methods: In total, 10 men with prostate cancer under ADH who were suffering with HF entered this study. Self-report questionnaire was used for the evaluation. Results: The average rating for HF frequency decreased (P ¼ 0.009) and HF severity decreased (P ¼ 0.0332) also, reported QOL score increased (P ¼ 0.0218). Conclusion: These preliminary data suggest that low dose (10 mg/day) of antidepressant paroxetine can be helpful in the treatment of HFs in patients under ADT for prostate cancer. Further controlled studies are needed to more fully evaluate the efficacy of the SSRIs.
Introduction
Vasomotor symptoms, or hot flashes (HFs), are frequent side effects of hormonal ablation and can be distressing to the patient. In a retrospective study, Karling et al. 1 reported that 68% of men had HFs during treatment with medical or surgical castration, and that symptoms generally did not subside with time on treatment, with 48% of men experiencing symptoms at 5 years and 40% of men continuing to experience symptoms at 8 years. A HF is a transient sensation of heat or without objective signs of skin vasodilation and is often accompanied with varying degrees of sweating, flushing, palpitations, anxiety, irritability, and even panic. 2 Vasomotor symptoms associated with cancer therapies represent an increasingly common problem for prostate cancer patients. Androgen-deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. With the increasing indications for the use of ADT in the treatment of men with prostate cancer, side effects such as HFs, decreased libido, decreased sexual function, and fatigue of the therapy deserve greater attention. Long-time ADT sometimes cause vasomotor side effects. HFs have been reported to interfere with daily activities and sleep. Also, HFs may be a significant clinical problem in men undergoing ADT with gonadotropin releasing hormone analogs, oral antiandrogens and/or surgical bilateral orchiectomy and some of prostate cancer patients have considered discontinuing ADT. Several nonhormonal agents have been reported to reduce HFs. These agents include clonidine, vitamin E, and soy supplementation. However, these agents are only moderately more effective than placebo. Thus, a well-tolerated nonhormonal treatment for HFs would be of great value. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression. Besides, it is known that SSRI is effective for HFs of breast cancer patients. 1 Loptinzi suggested that 12.5-37.5 mg/day of paroxetine is effective for reducing HFs in men receiving ADT. 3 In their study, it was concluded that it seems reasonable to use 12.5 mg/day of paroxetine, with the option to increase to 25.0 mg/day if needed. Based on the result, we evaluated whether low dose (10 mg/day) of paroxetine (SSRIs) reduce the frequency and severity of HFs in patients who have undergone ADT for prostate cancer.
Patients and methods
From July 2005 to November 2005, 10 patients entered the study. Patients included in this study were men with prostate cancer under ADT for prostate cancer (Table 1) and were evaluated for drug efficacy. A subject was deemed ineligible for the study if the patient; (1) was treated with paroxetine in the last 6 months; (2) had a hypersensitivity to paroxetine; (3) had multiple drug allergies; (4) had any clinically significant uncontrolled or unstable medical disease; (5) had a myocardia infarction in the last 6 months; and (6) had a history or presence of any psychotic disorder. Also, patients were not allowed to be receiving antineoplastic chemotherapy, estrogens, progestational drugs, or chinese medicine except for ADT drugs. Additionally, to be included in this study, patients must have had a history of at least seven HFs per week, for a period of at least 1 month. All 10 patients were evaluable for safety and tolerability. The patients' characteristics are summarized in Table 1 . Following completion of the interview and blood examination, subjects were given paroxetine, 10 mg orally every morning.
Treatment evaluation
Self-report methods were used because the patients' evaluation of symptoms was of principal importance and greatest clinical relevance. 4 Data on HFs were obtained before the treatment and at first, second, third, and fourth week during the treatment. The diary consisted of self-administered questionnaires on the number of hot flushes during a day, severity of HFs (severity grade; 1: not at all, 5: intermediate, 10: extremely severe) and rate their lives on a scale (from 1: worst possible life to 10: best possible life) at each assessment was incorporated. Pill count was performed to test for compliance. Also, blood examinations (WBC, Hb, BUN creatinine, GOT, GPT) were performed before and 4 weeks after the treatment for to evaluate the biochemical adverse effect of this drug. Additionally, potential side effects were asked to the patients at fourth week.
Statistical analysis
Three measures of HFs symptoms were used to assess treatment effectiveness: frequency in a day, mean severity grade, QOL score of their lives. Frequency, severity grade, and QOL score of their lives at baseline and during the treatment were expressed as percentage changes from the baseline. Changes of the frequency, severity score, and QOL scores between baseline and week 4 were analyzed using Paired t-test.
Results
A total of 10 patients participated in the study. All the patients were under ADT for prostate cancer (Stage II ¼ 6, III ¼ 1, IV ¼ 3). The mean age for the sample was 70.7 years (range: 60-82 years). Further demographic and medical information for the study participants are listed in Table 1 . All patients attained a dose of paroxetin 10 mg taken in morning and none had any significant adverse reactions that require discontinuation from the study. All patients were experiencing HFs at base line (mean ¼ 3.50/day). Likewise, all patients were complaining HFs rated 'quite a bit' or 'extremely' severe at base line (mean ¼ 3.80). Following the 4 weeks administration of 10 mg/day of paroxetine, the average rating for HF frequency decreased significantly (mean ¼ 3.5/day to mean ¼ 2.0/day, P ¼ 0.009) (Figure 1a) . Also, the average rating for HF severity decreased significantly (mean ¼ 4.6-2.0, P ¼ 0.0332) (Figure 1b) . Similarly, reported QOL score improved significantly (mean ¼ 3.8 ¼ 6.9, P ¼ 0.0218) (Figure 1c ). (Change of each patients' frequency, severity, and QOL scores are showed in Table 2 .) Mean levels of HF frequency, severity and QOL score before and 4 weeks after administration of 10 mg/day of paroxetine are listed in Table 3 . Adverse effects were minimal and included mostly dry mouth (5/10: 50%) and somnolence (4/10: 40%) (Table 4) . Also, nonhematological toxicities (including: WBC, Hb, BUN creatinine, GOT, GPT) were observed after 4 weeks administration of 10 mg/day of paroxetine (data not shown). No patient discontinued paroxetine therapy due to adverse effect. Only one patient (1/10: 10%) discontinued the paroxetine after the study, because the patient was not satisfied with the efficacy of paroxetine.
Discussion
HFs are a major clinical problem for many women as they enter menopause and also for men who have undergone ADT for prostate cancer. ADT for managing prostate cancer has become increasingly popular. The treatment aims to deprive cancer cells of androgens; the leading methods are bilateral orchidectomy and the administration of LH-RH analogs. After bilateral orchidectomy about half of patients have hot flushes and they tend to occur within a few months. 5, 6 With LH-RH analogs, the incidence of hot flushes is approximately Pilot evaluation of SSRI antidepressants in HF patients M Naoe et al 60-70%. 7, 8 However, consideration should be given to the fact that the actual number of patients experiencing HF could be much higher. Exposure to ADH and its side effects is lengthy, and because it is palliative, side effects must be addressed and treated effectively. Although HF is not a serious adverse effect, when it become severe and frequent it can be very annoying to the patient, and interfere patients quality of life, and some of prostate cancer patients have considered discontinuing ADT. Therefore the available treatments should be considered and treatment should be individualized and administered after balancing the benefits and risks. Although the pathophysiology underlying HF induced by ADT is not entirely clear, Beckman's theory has been considered predominant. 9 With animal experiments, Beckman showed that the intrahypothalamic administration of noradrenaline affects thermoregulation. The thermoregulatory center in the hypothalamus is anatomically close to the GnRH (LH-RH) secreting neurones. These neurones are stimulated by noradrenaline to secrete LH-RH. Increased hypothalamic noradrenaline therefore stimulates LH-RH neurones and by proximity resets the thermoregulatory center (i.e. the 'watering-can' effect) to activate heat-losing mechanisms. These include cutaneous vasodilatation and profuse perspiration. So, treatment for restore the regulatory negative feedback would reasonable. For the reason, oestrogens (DES) and progesterones and androgens have been tried. However, Table 2 Changes of frequency, severity of HF and QOL score before and 4 weeks after paroxetine in 10 patients
Patient
Frequency/day Severity score QOL score
Abbreviation: HF, hot flash. [12] [13] [14] Thus, a well-tolerated nonhormonal agent for HF is needed. Newer antidepressants such as SSRIs and inhibitors of serotonin and norepinephrine reuptake, are promising nonhormonal treatments for HFs. Randomized placebo-controlled trials have shown that venlafaxine, 15 fluoxetine, 16 and gabapentine 17 are effective in control of HFs. A differential effect of the newer antidepressants on HF is consistent with the known differential effect of such drugs on depressive symptoms in individual patients. Also, toxicities differ among the newer antidepressants 18 illustrating that these drugs have varying effects. Within those antidepressants, it is reported that SSRI is relatively effective agent for alleviating HFs. 4, 9 Also, Loprinzi et al. 3 reported relatively good results of a pilot evaluation of the 12.5 mg/ day of paroxetine in prostate cancer patients on ADT. Paroxetine is in a class of drugs called SSRIs, a class that also contains fluoxetine (Prozac) and sertraline (Zoloft). Within those SSRIs, it is known that the incidence of nausea caused by side effect of paroxetin is relatively low. Thus, we choose paroxetine for this study. As it has reported that low dose (10-20 mg/day) of paroxetine is effective and safe for HF patients with breast cancer survivor, 19 we propose that 10 mg/day is reasonable initial dosages. In this study, efficacy of low dose of paroxetine (10 mg/day) were observed at first week in three patients (3/10: 30%), second week in three patients (3/10: 30%), third week in two patients (2/10: 20%) and fourth week in two patients (2/10 20%), so the progress of HF symptoms should be observed for at least 4 weeks and if symptoms do not improve within a month, the dosage can be increased. However, it is important to keep in mind that this is a pilot trial, as opposed to a placebo-controlled trial. In conclusion, the data from this pilot study suggest that 10 mg/day of paroxetine is an effective treatment for HF patients who have undergone ADT for prostate cancer. Further study on dosing, duration of treatment is needed to further define the role of SSRIs in the treatment of HFs. Also, the treatment for HF should be individualized and administered after balancing the benefits and risks.
